Amarin Corporation Plc (AMRN) 1.66 $AMRN
Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations
Marketwire - Fri Aug 08, 5:25AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and six months ended June 30, 2014, and provided an update on company operations.
Amarin to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 7, 2014
ACCESSWIRE - Thu Aug 07, 8:33AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / August 7, 2014 / Amarin Corporation plc (NASDAQ:AMRN) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Thursday, August 7, 2014 at 4:30 PM Eastern Time.
Amarin to Report Second Quarter 2014 Results and Host Conference Call on August 7, 2014
Marketwire - Tue Aug 05, 6:04AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2014 financial results and provide an operational update on Thursday, August 7, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's second quarter 2014 financial results earlier that day.
Stock to Watch: Amarin Up 7.7% (AMRN)
Comtex SmarTrend(R) - Thu Jul 31, 10:11AM CDT
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 7.7% to $1.71 on 4.3x average daily volume. Amarin has traded 7.1 million shares thus far today, vs. average volume of 1.7 million shares per day. The stock has outperformed the Dow (7.7% to the Dow's -1.1%) and outperformed the S&P 500 (7.7% to the S&P's -1.4%) during today's trading.
Amarin Shocker: There's a Reason to be Bullish Right Now
at The Street - Thu Jul 31, 8:02AM CDT
If an FDA appeal decision goes in Amarin's favor, the stock is moving much higher.
Health Care Sector Stocks Technical Review: Valeant Pharma, Teva Pharma Industries, Novo Nordisk, Curis, and Amarin
PR Newswire - Thu Jul 17, 7:10AM CDT
On Wednesday, July 16, 2014, the NASDAQ Composite ended at 4,425.97, up 0.22%, the Dow Jones Industrial Average finished the day 0.45% higher at 17,138.20, and the S&P 500 closed at 1,981.57, up 0.42%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 706.97, down 0.29%, while the index has advanced 2.56% in the last one month. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Novo Nordisk (NYSE: NVO), Curis Inc. (NASDAQ: CRIS), and Amarin Corp PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at:
3 Things to Look for in MannKind's Partnership
Brian Orelli, The Motley Fool - Motley Fool - Fri Jul 04, 4:00PM CDT
It's been a week since MannKind gained Food and Drug Administration approval for its inhaled insulin Afrezza, and the biotech still hasn't announced a marketing partner. What's taking so long? I jest. But I'm allowed to. MannKind has been...
Rick Harrison of Television's "Pawn Stars®" Discusses His Revelations on Seeking Treatment for His Very High Triglycerides in National Awareness Campaign
PR Newswire - Wed Jun 25, 5:30AM CDT
Amarin Corporation, plc (Nasdaq: AMRN), today announced a national partnership with Rick Harrison, star of the hit television show "Pawn Stars®," in launching Lower My Trigs(TM), a national awareness campaign about seeking treatment for very high triglycerides (VHTG) (> 500 mg/dL), a problem faced by up to four million Americans. Amarin has engaged Harrison as a spokesperson for the campaign to inform patients and family members, their physicians and other health care professionals about the health risks of very high triglycerides and the importance of patients discussing available treatment options with their physician.
Of These 3 Battleground Biotech Stocks, 1 Is a Buy
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 9:26AM CDT
The Biotech Banter crew is getting into the World Cup spirit, looking at foreign biotechs to see whether they're investable. First up: Amarin has a drug on the market, but unfortunately its fish oil Vascepa has struggled to gain much...
Biotech 101: Off-Label Prescriptions
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 8:21PM CDT
When the Food and Drug Administration approves a drug, it's given a label, although there's no sticky stuff on the back and it's not attached to the bottle. Drug labels are multipage documents that list everything from the chemical description of the...
Amarin Up 5.2%, Shares Break Through Resistance (AMRN)
Comtex SmarTrend(R) - Thu Jun 19, 10:38AM CDT
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 5.2% to $1.63 on 1.4x average daily volume. Thus far today, Amarin has traded 2.2 million shares, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.2%) and outperformed the S&P 500 (5.2% to the S&P's -0.1%) during today's trading.
Stock Watchout on Biotech Industry -- Research on Isis Pharma, Pharmacyclics, Amarin, and Prana Biotechnology
PR Newswire - Wed Jun 11, 6:10AM CDT
The US markets on Tuesday, June 10, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,945.92, up 0.02% and the NASDAQ Composite closed at 4,338.00, up 0.04%. The S&P 500 finished the session 0.02% lower at 1,950.79. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 692.83, up 0.21%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Pharmacyclics Inc. (NASDAQ: PCYC), Amarin Corp. PLC (NASDAQ: AMRN) and Prana Biotechnology Ltd (NASDAQ: PRAN). Free technical research on ISIS, PCYC, AMRN and PRAN can be downloaded upon signing up at:
Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)
Marketwire - Wed Jun 11, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the publication of a retrospective analysis of patient cases that examined the effect on lipid parameters in hyperlipidemic patients who were switched from Lovaza® (omega-3-acid ethyl esters) capsules, a mixture of omega fatty acids, to Vascepa® (icosapent ethyl) capsules, the only pure-EPA prescription omega-3 product, to potentially achieve better outcomes in triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels.1 During the studied period, most of the 14 patients switched to Vascepa experienced reductions in levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C).
Amarin to Present at the Goldman Sachs 2014 Global Healthcare Conference
Marketwire - Thu Jun 05, 2:15AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Goldman Sachs 2014 Global Healthcare Conference on Wednesday, June 11, 2014, at 3:20 p.m. PT.
Can This Drive Growth for Amarin Corporation plc?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 01, 1:30PM CDT
Small-cap biopharmaceutical Amarin has made it clear that the company is not giving up on Vascepa without a fight, several of them actually. In addition to challenging the FDA's decisions to rescind a Special Protocol Assessment (SPA) on the...
Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Amarin Corporation plc (Nasdaq:AMRN) and Kowa Pharmaceuticals America, Inc., two biopharmaceutical companies focused on the development and commercialization of therapeutics to improve cardiovascular health, today announced an agreement to co-promote Amarin's flagship product, Vascepa (icosapent ethyl) capsules, in the United States. Vascepa is approved for use in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater-than or equal to 500 mg/dL) hypertriglyceridemia. In bringing together two companies focused on the primary care and cardiovascular health communities, the agreement is designed to benefit a greater number of patients.
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at:
Amarin Corporation plc. Analyst Report: Special Situation \ Turnaround Opportunity in Biopharmaceuticals - Targeting large existing cardiovascular health market by BrokerBank Securities, Inc.
PR Newswire - Fri Mar 28, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), an established biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health is in the process of attempting a turnaround to return to a growth trajectory. The Company's lead product, Vascepa (icosapent ethyl) capsules, is approved by the U.S. FDA for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Mar 28, 5:00AM CDT
Keep these under-$10 biotech stocks on your radar.
Better Chance of Making a Comeback: Amarin plc or VIVUS, Inc.?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
I am a strong advocate of investing in so-called "comeback stories." My belief is underscored by the notable comebacks of Best Buy and Netflix in recent times. Within a few short months , Best Buy gained more than 200% and Netflix did even...
Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations
Marketwire - Fri Aug 08, 5:25AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and six months ended June 30, 2014, and provided an update on company operations.
Amarin to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 7, 2014
ACCESSWIRE - Thu Aug 07, 8:33AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / August 7, 2014 / Amarin Corporation plc (NASDAQ:AMRN) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Thursday, August 7, 2014 at 4:30 PM Eastern Time.
Amarin to Report Second Quarter 2014 Results and Host Conference Call on August 7, 2014
Marketwire - Tue Aug 05, 6:04AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2014 financial results and provide an operational update on Thursday, August 7, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's second quarter 2014 financial results earlier that day.
Stock to Watch: Amarin Up 7.7% (AMRN)
Comtex SmarTrend(R) - Thu Jul 31, 10:11AM CDT
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 7.7% to $1.71 on 4.3x average daily volume. Amarin has traded 7.1 million shares thus far today, vs. average volume of 1.7 million shares per day. The stock has outperformed the Dow (7.7% to the Dow's -1.1%) and outperformed the S&P 500 (7.7% to the S&P's -1.4%) during today's trading.
Amarin Shocker: There's a Reason to be Bullish Right Now
at The Street - Thu Jul 31, 8:02AM CDT
If an FDA appeal decision goes in Amarin's favor, the stock is moving much higher.
Health Care Sector Stocks Technical Review: Valeant Pharma, Teva Pharma Industries, Novo Nordisk, Curis, and Amarin
PR Newswire - Thu Jul 17, 7:10AM CDT
On Wednesday, July 16, 2014, the NASDAQ Composite ended at 4,425.97, up 0.22%, the Dow Jones Industrial Average finished the day 0.45% higher at 17,138.20, and the S&P 500 closed at 1,981.57, up 0.42%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 706.97, down 0.29%, while the index has advanced 2.56% in the last one month. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Novo Nordisk (NYSE: NVO), Curis Inc. (NASDAQ: CRIS), and Amarin Corp PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at:
3 Things to Look for in MannKind's Partnership
Brian Orelli, The Motley Fool - Motley Fool - Fri Jul 04, 4:00PM CDT
It's been a week since MannKind gained Food and Drug Administration approval for its inhaled insulin Afrezza, and the biotech still hasn't announced a marketing partner. What's taking so long? I jest. But I'm allowed to. MannKind has been...
Rick Harrison of Television's "Pawn Stars®" Discusses His Revelations on Seeking Treatment for His Very High Triglycerides in National Awareness Campaign
PR Newswire - Wed Jun 25, 5:30AM CDT
Amarin Corporation, plc (Nasdaq: AMRN), today announced a national partnership with Rick Harrison, star of the hit television show "Pawn Stars®," in launching Lower My Trigs(TM), a national awareness campaign about seeking treatment for very high triglycerides (VHTG) (> 500 mg/dL), a problem faced by up to four million Americans. Amarin has engaged Harrison as a spokesperson for the campaign to inform patients and family members, their physicians and other health care professionals about the health risks of very high triglycerides and the importance of patients discussing available treatment options with their physician.
Of These 3 Battleground Biotech Stocks, 1 Is a Buy
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 9:26AM CDT
The Biotech Banter crew is getting into the World Cup spirit, looking at foreign biotechs to see whether they're investable. First up: Amarin has a drug on the market, but unfortunately its fish oil Vascepa has struggled to gain much...
Biotech 101: Off-Label Prescriptions
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 8:21PM CDT
When the Food and Drug Administration approves a drug, it's given a label, although there's no sticky stuff on the back and it's not attached to the bottle. Drug labels are multipage documents that list everything from the chemical description of the...
Amarin Up 5.2%, Shares Break Through Resistance (AMRN)
Comtex SmarTrend(R) - Thu Jun 19, 10:38AM CDT
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 5.2% to $1.63 on 1.4x average daily volume. Thus far today, Amarin has traded 2.2 million shares, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.2%) and outperformed the S&P 500 (5.2% to the S&P's -0.1%) during today's trading.
Stock Watchout on Biotech Industry -- Research on Isis Pharma, Pharmacyclics, Amarin, and Prana Biotechnology
PR Newswire - Wed Jun 11, 6:10AM CDT
The US markets on Tuesday, June 10, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,945.92, up 0.02% and the NASDAQ Composite closed at 4,338.00, up 0.04%. The S&P 500 finished the session 0.02% lower at 1,950.79. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 692.83, up 0.21%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Pharmacyclics Inc. (NASDAQ: PCYC), Amarin Corp. PLC (NASDAQ: AMRN) and Prana Biotechnology Ltd (NASDAQ: PRAN). Free technical research on ISIS, PCYC, AMRN and PRAN can be downloaded upon signing up at:
Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)
Marketwire - Wed Jun 11, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the publication of a retrospective analysis of patient cases that examined the effect on lipid parameters in hyperlipidemic patients who were switched from Lovaza® (omega-3-acid ethyl esters) capsules, a mixture of omega fatty acids, to Vascepa® (icosapent ethyl) capsules, the only pure-EPA prescription omega-3 product, to potentially achieve better outcomes in triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels.1 During the studied period, most of the 14 patients switched to Vascepa experienced reductions in levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C).
Amarin to Present at the Goldman Sachs 2014 Global Healthcare Conference
Marketwire - Thu Jun 05, 2:15AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Goldman Sachs 2014 Global Healthcare Conference on Wednesday, June 11, 2014, at 3:20 p.m. PT.
Can This Drive Growth for Amarin Corporation plc?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 01, 1:30PM CDT
Small-cap biopharmaceutical Amarin has made it clear that the company is not giving up on Vascepa without a fight, several of them actually. In addition to challenging the FDA's decisions to rescind a Special Protocol Assessment (SPA) on the...
Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Amarin Corporation plc (Nasdaq:AMRN) and Kowa Pharmaceuticals America, Inc., two biopharmaceutical companies focused on the development and commercialization of therapeutics to improve cardiovascular health, today announced an agreement to co-promote Amarin's flagship product, Vascepa (icosapent ethyl) capsules, in the United States. Vascepa is approved for use in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater-than or equal to 500 mg/dL) hypertriglyceridemia. In bringing together two companies focused on the primary care and cardiovascular health communities, the agreement is designed to benefit a greater number of patients.
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at:
Amarin Corporation plc. Analyst Report: Special Situation \ Turnaround Opportunity in Biopharmaceuticals - Targeting large existing cardiovascular health market by BrokerBank Securities, Inc.
PR Newswire - Fri Mar 28, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), an established biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health is in the process of attempting a turnaround to return to a growth trajectory. The Company's lead product, Vascepa (icosapent ethyl) capsules, is approved by the U.S. FDA for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Mar 28, 5:00AM CDT
Keep these under-$10 biotech stocks on your radar.
Better Chance of Making a Comeback: Amarin plc or VIVUS, Inc.?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
I am a strong advocate of investing in so-called "comeback stories." My belief is underscored by the notable comebacks of Best Buy and Netflix in recent times. Within a few short months , Best Buy gained more than 200% and Netflix did even...
